553 research outputs found
Integrating medical knowledge to improve science with a novel, straightforward attitude: the bio-integrative medicine
[no abstract available
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
Target Therapies in Lung Cancer
Targeting intracellular signaling molecules is an attractive approach for treatment of malignancies. In particular lung cancer has reached a plateau regarding overall survival, and target therapies could offer the possibility to improve patients' outcome beyond cytotoxic activity. The goal for target therapies is to identify agents that target tumor-specific molecules, thus sparing normal tissues; those molecules are called biomarkers, and their identification is recommended because it has a predictive value, for example, provides information on outcome with regard to a specific treatment. The increased specificity should lead to decreased toxicity and better activity. Herein we provide an update of the main target therapies in development or already available for the treatment of nonsmall cell lung cancer
Use of complementary and alternative medicine (CAM) in cancer patients. An italian multicenter survey
INTRODUCTION:
Complementary and Alternative Medicine (CAM) include a wide range of products (herbs, vitamins, minerals, and probiotics) and medical practices, developed outside of the mainstream Western medicine. Patients with cancer are more likely to resort to CAM first or then in their disease history; the potential side effects as well as the costs of such practices are largely underestimated.
PATIENTS AND METHOD:
We conducted a descriptive survey in five Italian hospitals involving 468 patients with different malignancies. The survey consisted of a forty-two question questionnaire, patients were eligible if they were Italian-speaking and receiving an anticancer treatment at the time of the survey or had received an anticancer treatment no more than three years before participating in the survey.
RESULTS:
Of our patients, 48.9% said they use or have recently used CAM. The univariate analysis showed that female gender, high education, receiving treatment in a highly specialized institute and receiving chemotherapy are associated with CAM use; at the multivariate analysis high education (Odds Ratio, (OR): 1.96 95% Confidence Interval, CI, 1.27-3.05) and receiving treatment in a specialized cancer center (OR: 2.75 95% CI, 1.53-4.94) were confirmed as risk factors for CAM use.
CONCLUSION:
Roughly half of our patients receiving treatment for cancer use CAM. It is necessary that health professional explore the use of CAM with their cancer patients, educate them about potentially beneficial therapies in light of the limited available evidence of effectiveness, and work towards an integrated model of health-care provision
The cost function of the data fusion process and its application
When the complete data fusion method is used to fuse
inconsistent measurements, it is necessary to add to the measurement
covariance matrix of each fusing profile a covariance matrix that takes into
account the inconsistencies. A realistic estimate of these inconsistency
covariance matrices is required for effectual fused products. We evaluate
the possibility of assisting the estimate of the inconsistency covariance
matrices using the value of the cost function minimized in the complete data
fusion. The analytical expressions of expected value and variance of the
cost function are derived. Modelling the inconsistency covariance matrix
with one parameter, we determine the value of the parameter that makes the
reduced cost function equal to its expected value and use the variance to
assign an error to this determination. The quality of the inconsistency
covariance matrix determined in this way is tested for simulated
measurements of ozone profiles obtained in the thermal infrared in the
framework of the Sentinel-4 mission of the Copernicus programme. As
expected, the method requires sufficient statistics and poor results are
obtained when a small number of profiles are being fused together, but very
good results are obtained when the fusion involves a large number of
profiles.</p
Novel mutations in the WFS1 gene are associated with Wolfram syndrome and systemic inflammation
Mutations in the WFS1 gene, encoding wolframin (WFS1), cause endoplasmic reticulum (ER) stress and are associated with a rare autosomal-recessive disorder known as Wolfram syndrome (WS). WS is clinically characterized by childhood-onset diabetes mellitus, optic atrophy, deafness, diabetes insipidus and neurological signs. We identified two novel WFS1 mutations in a patient with WS, namely, c.316-1G > A (in intron 3) and c.757A > T (in exon 7). Both mutations, located in the N-terminal region of the protein, were predicted to generate a truncated and inactive form of WFS1. We found that although the WFS1 protein was not expressed in peripheral blood mononuclear cells (PBMCs) of the proband, no constitutive ER stress activation could be detected in those cells. In contrast, WS proband's PBMCs produced very high levels of proinflammatory cytokines (i.e. TNF-α, IL-1β, and IL-6) in the absence of any stimulus. WFS1 silencing in PBMCs from control subjects by means of small RNA interference also induced a pronounced proinflammatory cytokine profile. The same cytokines were also significantly higher in sera from the WS patient as compared to matched healthy controls. Moreover, the chronic inflammatory state was associated with a dominance of proinflammatory T helper 17 (Th17)-type cells over regulatory T (Treg) lymphocytes in the WS PBMCs. The identification of a state of systemic chronic inflammation associated with WFS1 deficiency may pave the way to innovative and personalized therapeutic interventions in WS
Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART?
Recommended from our members
Indirect structural health monitoring (iSHM) of transport infrastructure in the digital age
Workshop reportCopyright © Joint Research Centre (European Commission). The existing European motorway infrastructure network is prone to ageing and subject to natural events (e.g. climate change) and hazards (e.g. earthquakes), necessitating immediate actions for its maintenance and
safety. Within this context, the structural health monitoring (SHM) framework allows a quantitative assessment of the structural integrity, serviceability and performance, facilitating better-informed decisions for the management of the existing infrastructure. The European Commission Joint Research Centre (JRC) established the exploratory research project MITICA (Monitoring Transport Infrastructures with Connected and Automated vehicles) to investigate the opportunity to use novel methods for infrastructure motoring, aiming at the efficient
maintenance of the European aging road infrastructure. This report summarizes the discussion and the outcomes of a workshop held at the JRC in Ispra (Italy) on June 6-7 2022, as part of the MITICA project.
Considering the EU priority “A Europe fit for the digital age”, the workshop was dedicated to SHM and its application to civil infrastructure, focusing on innovative indirect structural health monitoring (iSHM) approaches that rely on the vehicle-bridge interaction and the deployment of sensor-equipped vehicles for the monitoring of the existing bridge infrastructure. The report aims to become a reference document in the area of iSHM using passing vehicles, for both scholars and policy makers
γ-Herpesvirus load as surrogate marker of early death in HIV-1 lymphoma patients submitted to high dose chemotherapy and autologous peripheral blood stem cell transplantation
Autologous stem cell transplantation (ASCT) is a feasible procedure for human immunodeficiency virus-1 (HIV-1) lymphoma patients, whose underlying disease and intrinsic HIV-1-and ASCT-associated immunodeficiency might increase the risk for \u3b3-herpesvirus load persistence and/or reactivation. We evaluated this hypothesis by investigating the levels of Epstein-Barr virus (EBV)- and Kaposi sarcoma-associated herpesvirus (KSHV)-DNA levels in the peripheral blood of 22 HIV-1-associated lymphoma patients during ASCT, highlighting their relationship with \u3b3-herpesvirus lymphoma status, immunological parameters, and clinical events. EBV-DNA was detected in the pre-treatment plasma and peripheral blood mononuclear cells (PBMCs) of 12 (median 12135 copies/mL) and 18 patients (median 417 copies/106 PBMCs), respectively; the values in the two compartments were correlated (r = 0.77, p = 0.0001). Only EBV-positive lymphomas showed detectable levels of plasma EBV-DNA. After debulking chemotherapy, plasma EBV-DNA was associated with lymphoma chemosensitivity (p = 0.03) and a significant higher mortality risk by multivariate Cox analysis adjusted for EBV-lymphoma status (HR, 10.46, 95% CI, 1.11-98.32, p = 0.04). After infusion, EBV-DNA was detectable in five EBV-positive lymphoma patients who died within six months. KSHV-DNA load was positive in only one patient, who died from primary effusion lymphoma. Fluctuations in levels of KSHV-DNA reflected the patient's therapy and evolution of his underlying lymphoma. Other \u3b3-herpesvirus-associated malignancies, such as multicentric Castleman disease and Kaposi sarcoma, or end-organ complications after salvage treatment were not found. Overall, these findings suggest a prognostic and predictive value of EBV-DNA and KSHV-DNA, the monitoring of which could be a simple, complementary tool for the management of \u3b3-herpesvirus-positive lymphomas in HIV-1 patients submitted to ASCT
Lung cancer in HIV patients and their parents: A Danish cohort study
<p>Abstract</p> <p>Background</p> <p>HIV patients are known to be at increased risk of lung cancer but the risk factors behind this are unclear.</p> <p>Methods</p> <p>We estimated the cumulative incidence and relative risk of lung cancer in 1) a population of all Danish HIV patients identified from the Danish HIV Cohort Study (n = 5,053) and a cohort of population controls matched on age and gender (n = 50,530) (study period; 1995 - 2009) and 2) their parents (study period; 1969 - 2009). Mortality and relative risk of death after a diagnosis of lung cancer was estimated in both populations.</p> <p>Results</p> <p>29 (0.6%) HIV patients vs. 183 (0.4%) population controls were diagnosed with lung cancer in the observation period. HIV patients had an increased risk of lung cancer (adjusted incidence rate ratio (IRR); 2.38 (95% CI; 1.61 - 3.53)). The IRR was considerably increased in HIV patients who were smokers or former smokers (adjusted IRR; 4.06 (95% CI; 2.66 - 6.21)), male HIV patients with heterosexual route of infection (adjusted IRR; 4.19 (2.20 - 7.96)) and HIV patients with immunosuppression (adjusted IRR; 3.25 (2.01 - 5.24)). Both fathers and mothers of HIV patients had an increased risk of lung cancer (adjusted IRR for fathers; 1.31 (95% CI: 1.09 - 1.58), adjusted IRR for mothers 1.35 (95% CI: 1.07 - 1.70)). Mortality after lung cancer diagnose was increased in HIV patients (adjusted mortality rate ratio 2.33 (95%CI; 1.51 - 3.61), but not in the parents. All HIV patients diagnosed with lung cancer were smokers or former smokers.</p> <p>Conclusion</p> <p>The risk was especially increased in HIV patients who were smokers or former smokers, heterosexually infected men or immunosuppressed. HIV appears to be a marker of behavioural or family related risk factors that affect the incidence of lung cancer in HIV patients.</p
- …